November 10, 2016
MSD will request the reimbursement listing of its immuno-oncology drug Keytruda (pembrolizumab) after it adds an approval-pending lung cancer indication, a company official told Jiho on November 9. MSD decided to skip the drug’s listing scheduled for later this month...read more